Onsolis regulatory update

BioDelivery said partner TTY Biopharm submitted an NDA to the Taiwan Food and Drug Administration for BEMA Fentanyl to treat breakthrough pain in opioid-tolerant patients. The submission triggers a $300,000 milestone payment to BioDelivery from TTY under a 2010 deal granting TTY exclusive rights to develop and commercialize adhesive disc formulation of fentanyl in Taiwan (see BioCentury, Oct. 18, 2010). ...